Summary
Cencora, Inc. (COR) reported a significant increase in revenue for both the three and six months ended March 31, 2024, driven primarily by strong performance in its U.S. Healthcare Solutions segment. This growth was fueled by higher unit volumes, increased sales of specialty products, and contributions from GLP-1 class drugs and COVID-19 vaccines. Despite increased operating expenses, particularly related to litigation and opioid expenses, the company demonstrated improved gross profit and operating income across its segments. Financially, the company shows robust revenue growth and managed its expenses effectively, leading to increased operating income. However, investors should note the substantial accrued litigation liability related to opioid settlements, which stands at $5.1 billion. While the company has a strong liquidity position with substantial cash and cash equivalents and access to credit facilities, the ongoing opioid litigation and the recent cybersecurity event present notable risks and require continued monitoring. The company also continues its share repurchase program and dividend payments, indicating a commitment to returning value to shareholders.
Financial Highlights
55 data points| Revenue | $68.41B |
| Cost of Revenue | $65.88B |
| Gross Profit | $2.54B |
| SG&A Expenses | $1.39B |
| Operating Income | $553.26M |
| Net Income | $420.77M |
| EPS (Basic) | $2.11 |
| EPS (Diluted) | $2.09 |
| Shares Outstanding (Basic) | 199.41M |
| Shares Outstanding (Diluted) | 201.18M |
Key Highlights
- 1Revenue increased by 7.8% to $68.4 billion for the three months ended March 31, 2024, and by 11.4% to $140.7 billion for the six-month period, largely driven by the U.S. Healthcare Solutions segment.
- 2Gross profit saw a healthy increase of 10.6% and 12.7% for the respective periods, boosted by higher sales and favorable LIFO credits compared to prior year LIFO expenses.
- 3Operating income increased by 10.9% and 15.2% for the three and six-month periods respectively, reflecting strong performance in both U.S. and International Healthcare Solutions segments.
- 4The company has accrued $5.1 billion for opioid litigation settlements as of March 31, 2024, with a portion of this liability expected to be paid within the next year.
- 5Cash and cash equivalents stood at $2.1 billion as of March 31, 2024, with significant availability under credit facilities, indicating a strong liquidity position.
- 6The company repurchased $436.4 million of its common stock in the first six months of fiscal 2024 and has $2.37 billion remaining under its share repurchase programs.
- 7Litigation and opioid-related expenses, net, significantly increased in the current period, impacting overall operating expenses, with a notable $214.0 million accrual for ongoing opioid litigation in the first quarter of 2024.